Navigation Links
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
Date:11/13/2008

LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) (the "Company") has entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The agreement, dated November 11, 2008 states that CNG can fund up to $15,000,000 of the clinical development for the Company's Coronary Heart Disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CVBT's cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.

"CVBT is currently utilizing clinical development agreements to fund and advance our drug development candidates," according to Mr. Mickael A. Flaa, CVBT's Chief Financial Officer. Mr. Flaa continued, "Given the stress in the financial markets at this time, we looked to the lessons of history for a strategy to finance CVBT's drug development program. The clinical development arrangements that CVBT has entered into are similar in structure to those used successfully by Amgen, Genentech, Biogen, and others over 20 years ago to fund their drug development programs."

"This development agreement is a positive step in advancing CVBT's CHD drug candidate given today's financial markets," said Mr. Daniel C. Montano, CVBT's CEO. Mr. Montano continued, "I believe that CVBT's existing shareholders will benefit from this new source of funding which does not permanently dilute their shareholdings."

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , , BEIJING, Nov. 25 /PRNewsw...g developer and provider of vaccines, announced to...t to establish Sinovac (Dalian) Vaccine,Technology... develop, produce,and commercialize human-use vacc...perience in developing and commercializing world-c...
(Date:11/24/2009)... , Ambassador to also Vis...mber 24, 2009 -- , , ,Who: David Appia, French Amb... and CEO of the Invest in France Agency, , , , ,W...ess to discuss recent pro-business initiatives ado...iscal and academic landscape for innovation and de...
(Date:11/24/2009)... , , ST. LOUIS, Nov. 24 /PRNewswire-Fi...AL ) will be presenting at the NASDAQ OMX conferen...on, 7:45 AM US/CST. Interested parties may listen ...le at http://inve s tor.sig m a a ldrich.c...ss this file. ,, About Sigma-Aldrich: Sig...
(Date:11/24/2009)... , , SHANGHAI, Nov. 24 /PRNewswi... State Food & Drug Administration (SFDA) has a...IND) for its oral insulin project,(Nodlin), an inn...s IND,approval allows Biolaxy to initiate its firs... disorder characteristic of high blood glucose and...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Biolaxy Secures IND Approval for Oral Insulin 2
...aq: NXXI ), a growing developer and marketer of n...tes Essentials(TM) and Iceland Health(R) brands,th...ve cardiovascular,health, enhance memory, and addr...lts for the second quarter of fiscal year 2008, en..., after market close. The,Company has scheduled a ...
...) Brett Begemann, executive vice president of glob... vice president of strategy and,operations, will a...conferences later this month., Both Monsanto exec...iness performance and expectations, strategic init...ment pipeline, and other business matters,at these...
...n Company,s web site, GERMANTOWN, Md., Feb. 5 Mi...a pharmaceutical company focused on,developing and...day,announced that Dr. Edward M. Rudnic, MiddleBro...sentation on Monday, February 11, 2008, at 11:45,a...ce as part of the Biotechnology Industry,Organizat...
Other Biology Technology:Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008 2MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008 2
(Date:11/26/2009)... , MRSA (methicillin-resistant Staphylococcus Au...e annihilation as low-temperature plasma prototype... easy and unfailing bactericidal cocktails. , Tw...fficient disinfection of healthy skin (e.g. hands ...teria can pose a lethal threat; and another to sho...
(Date:11/25/2009)... , On September 11, firefighters, police officers...ffort in the World Trade Center complex. They batt..., searched for survivors, tackled fires and evacua...contained an estimated 17,000 people. And making t...unications: frightened workers and their relatives...
(Date:11/25/2009)... , Two Kent State University assistant professors...ce Foundation (NSF) to continue research beneficia...ts total $890,000. , Christopher Blackwood, assi...iences, was awarded grants to support two separate..."Assembling Litter Decomposer Communities and Func...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Cold Spring Harbor Laboratory 26apos 3Bs President Congratulates Alumna on Winning Nobel Prize 58919 1Cold Spring Harbor Laboratory 26apos 3Bs President Congratulates Alumna on Winning Nobel Prize 58919 2The American Academy of Family Physicians Launches Consumer Alliance With First Partner 3A The Coca Cola Company 58914 1The American Academy of Family Physicians Launches Consumer Alliance With First Partner 3A The Coca Cola Company 58914 2The American Academy of Family Physicians Launches Consumer Alliance With First Partner 3A The Coca Cola Company 58914 3The American Academy of Family Physicians Launches Consumer Alliance With First Partner 3A The Coca Cola Company 58914 4Sosei Assigns AD 923 Assets to Pharmasol 5243 1Sosei Assigns AD 923 Assets to Pharmasol 5243 2
...here Alzheimer,s, some cancers and genetic ills be...uncovered the pivotal role of a gene called "Cut" ...ommunication. , A DNA-binding protein, Cut interpr... through the "Notch" gene, which regulates a layer... But when Cut garbles those signals the result is ...
...iety of forms: particles, tubes, shells, even a so...ix: "nano," connoting their size, a billionth of a...y, cancer researchers are exploring the potential ...r cells without harming surrounding tissue, and to...ve a chance to become life-threatening. , While ...
...th an extra set of chromosomes can initiate the de...arber Cancer Institute have shown, validating a co...h by a scientific visionary nearly 100 years ago. ...by random errors in cell division that occur with ...ally unstable cells appears to be a "pathway for g...
Other Biology News:FSU biologists describe key role of signal-transcribing gene during cell cycle 2Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 2Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 3Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 4Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 5Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 6Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 7Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer 8Double trouble: Cells with duplicate genomes can trigger tumors 2Double trouble: Cells with duplicate genomes can trigger tumors 3
...o be "a delight to use" as it incorporates the fun...ng. With its ergonomic design and small footprint,...accommodated in a busy lab environment. The DM-BA3...cted Infinity System and infinity-corrected Plan o...
...ighest resolution standard for all Imaging Plate e...AS scanners, it features a superior Imaging Plate ...tility in target subjects. Fujifilm BAS-5000 does ...ighest resolution results are available immediatel...
Anti-human CD41 Tetramer, 200 uL from StemCell Technologies, Inc.
... use and rapid solutions to meet your laboratory's...rol. ...is the standard software for Staccato Systems and ...erface with more than 100 laboratory devices. It i...
Biology Products: